PFG Investments’s AbCellera Biologics ABCL Stock Holding History

PFG Investments’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,610	Closed	-$63.4K	–	1151
2025 Q3	$63.4K	Buy	12,610 +110	+0.9%	+$485	﹤0.01%	1075
2025 Q2	$42.9K	Hold	12,500	–	–	﹤0.01%	1015
2025 Q1	$27.9K	Sell	12,500 -1,500	-11%	-$4.3K	﹤0.01%	991
2024 Q4	$41K	Hold	14,000	–	–	﹤0.01%	988
2024 Q3	$36.4K	Sell	14,000 -1,100	-7%	-$3.05K	﹤0.01%	981
2024 Q2	$44.7K	Sell	15,100 -1,500	-9%	-$5.68K	﹤0.01%	898
2024 Q1	$75.2K	Buy	+16,600	New	+$84.7K	﹤0.01%	981

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PFG Investments's ABCL Position: Q4 2025 in Review

PFG Investments sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 12,610 shares — an estimated $63.4K sold.

PFG Investments first reported a position in ABCL in Q1 2024 and held it in 7 quarters. The position peaked at $75.2K in Q1 2024. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

PFG Investments reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
PFG Investments sold 12,610 AbCellera Biologics shares in Q4 2025, an estimated $63.4K.
PFG Investments first reported a position in AbCellera Biologics in Q1 2024 and held it in 7 quarters.
PFG Investments's AbCellera Biologics position peaked at $75.2K in Q1 2024.
144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on PFG Investments's 13F filing for Q4 2025, filed 26 Jan 2026.